Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[[Therapeutic perspectives in multiple sclerosis]

C Lubetzki, T Dubard, B Stankoff

    Presse Medicale (Paris, France : 1983)
    |June 15, 1996
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    In vivo molecular imaging of brain tissue pathology in presymptomatic multiple sclerosis.

    Revue neurologique·2025
    Same author

    Artificial intelligence in presymptomatic neurological diseases: Bridging normal variation and prodromal signatures.

    Revue neurologique·2025
    Same author

    Positive effect of evobrutinib in CNS remyelination models and lack of synergy with clemastine-A dose response study.

    Multiple sclerosis journal - experimental, translational and clinical·2025
    Same author

    Deleterious functional consequences of perfluoroalkyl substances accumulation into the myelin sheath.

    Environment international·2023
    Same author

    [

    European journal of nuclear medicine and molecular imaging·2023
    Same author

    A randomized double-blind placebo-controlled trial of low-dose interleukin-2 in relapsing-remitting multiple sclerosis.

    Journal of neurology·2023
    Same journal

    Predictive analytics and risk stratification models in internal medicine: from risk scores to real-time machine learning.

    Presse medicale (Paris, France : 1983)·2026
    Same journal

    Artificial Intelligence in skin disease therapeutics: from drug discovery to personalized treatment pathways.

    Presse medicale (Paris, France : 1983)·2026
    Same journal

    AI in clinical diagnostics in dermatology: applications, validation, and real-world use cases.

    Presse medicale (Paris, France : 1983)·2026
    Same journal

    Artificial Intelligence in medical research and publishing: progress, risks, and future perspectives.

    Presse medicale (Paris, France : 1983)·2026
    Same journal

    Ethical, legal, and regulatory challenges in AI-based healthcare tools.

    Presse medicale (Paris, France : 1983)·2026
    Same journal

    Decision-making for clinicians.

    Presse medicale (Paris, France : 1983)·2026
    See all related articles

    Current multiple sclerosis treatments offer limited clinical benefit. While interferons and copolymer I show promise in reducing relapse frequency, new therapeutic approaches are essential for improved long-term outcomes in multiple sclerosis management.

    Area of Science:

    • Neurology
    • Immunology
    • Clinical Therapeutics

    Background:

    • Multiple sclerosis (MS) research has seen numerous clinical trials in recent years, yielding some encouraging results but with limited overall clinical benefit.
    • Corticosteroids are used for severe relapses but lack long-term efficacy. Immunosuppressive agents may offer temporary help in highly active disease stages.

    Discussion:

    • Interferon beta-1b has demonstrated a moderate reduction in relapse frequency in relapsing MS.
    • Interferon beta-1a has shown similar effects on relapse frequency and may also impact disability progression.
    • Copolymer I also indicates potential in decreasing the frequency of relapses in multiple sclerosis patients.

    Key Insights:

    • Interferon therapies (beta-1a and beta-1b) represent a moderate advancement in managing relapsing multiple sclerosis.

    Related Experiment Videos

  • While some treatments show efficacy in reducing relapse rates, the long-term clinical benefit for multiple sclerosis patients remains a significant challenge.
  • Current therapeutic strategies for multiple sclerosis, including corticosteroids and immunosuppressants, have demonstrated limitations in providing sustained improvement.

    • Outlook:

    • Further clinical trials are imperative to explore novel therapeutic strategies for multiple sclerosis.
    • The development of new treatments targeting the underlying mechanisms of multiple sclerosis is crucial.
    • Continued research into advanced therapies is needed to improve long-term outcomes and patient quality of life in multiple sclerosis.